Revvity downgraded by Bernstein with a new price target
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 4/14/2026 | $95.00 | Overweight → Equal Weight | Barclays |
| 12/15/2025 | $110.00 | Buy → Neutral | BofA Securities |
| 12/9/2025 | $105.00 | Neutral | Goldman |
| 10/16/2025 | Neutral | Guggenheim | |
| 5/1/2025 | $115.00 | Neutral → Buy | UBS |
| 1/10/2025 | $130.00 | Outperform → Mkt Perform | Bernstein |
| 12/13/2024 | $138.00 | Neutral → Buy | BofA Securities |
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
SD - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the
The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni
Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and w
Wolfe Research resumed coverage of Revvity with a rating of Peer Perform
Barclays downgraded Revvity from Overweight to Equal Weight and set a new price target of $95.00
BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00
Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the
The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni
Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G - REVVITY, INC. (0000031791) (Subject)